Key result
Prior infection with the moderately virulent ASFV strain 'Estonia14' provided complete protection against lethal clinical disease when challenged with the highly virulent 'Armenia08' strain six months later.
Why the study?
African swine fever virus poses a major threat to pork production and wild pigs worldwide, prompting the evaluation of long-term fate and immunity following recovery from moderately virulent infection.
Does prior infection with moderately virulent ASFV 'Estonia14' prevent lethal disease upon challenge with highly virulent ASFV 'Armenia08' in pigs?
Does prior infection with moderately virulent ASFV 'Estonia14' prevent lethal disease upon challenge with highly virulent ASFV 'Armenia08' in pigs?
Absolute Event Rate: 100% vs 0%
Prior infection with a moderately virulent ASFV strain provides robust protective immunity against a highly virulent challenge 6 months later in pigs.
Recovered pigs may inform ASFV vaccine duration studies; leaves open field efficacy and licensing needs.
African swine fever virus (ASFV) poses a significant threat to pork production and wild pig populations worldwide. The study assessed the long-term fate and immunity of animals recovering from a moderately virulent ASFV infection, following the principles of a duration of immunity study for live vaccines. Pigs inoculated with the moderately virulent ASFV strain ‘ Estonia14 ’ largely developed mild clinical signs and only transient viremia. Six months after the initial inoculation and once fully recovered, all the animals were challenged with highly virulent ASFV ‘ Armenia08 ’. Only one of the previously exposed pigs exhibited mild clinical signs, while all control animals showed typical signs of acute, lethal ASF. Moreover, only a subset of pigs inoculated with the ASF strain ‘ Estonia14 ’ displayed temporary detectability of ASFV genomes following challenge infection. Virus isolation corroborated these findings, with low levels of infectious virus in organs of previously inoculated pigs (28 days post challenge). Furthermore, monitoring of IgM and IgG kinetics enabled the analysis of humoral responses. IgG levels were sustained over the study period and increased slightly upon challenge infection. Lastly, plasma analysis revealed elevated complement factor C3a levels post inoculation and challenge in the recovered pigs, directly correlating with challenge virus presence. In contrast, both C3a and C5a levels were increased in the control group. It could be shown that complement system activation was mediated by the lectin pathway, possibly by interaction of mannose-binding lectins and ASFV particles. This study suggests that protective immunity following recovery can last at least six months. No cases of persistent or chronic disease were observed in convalescent pigs. These findings have implications for both vaccine development and assessment, as well as for disease control strategies including surveillance actions.
No takes yet. Share an insight, caveat, or question.
Friedrichs et al. (2025) studied African swine fever virus (ASFV) infection (n=20). ASFV strain 'Estonia14' inoculation vs. Naive control group was evaluated on Survival and protection from severe clinical signs after highly virulent ASFV 'Armenia08' challenge. Prior infection with the moderately virulent ASFV strain 'Estonia14' provided complete protection against lethal clinical disease when challenged with the highly virulent 'Armenia08' strain six months later.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: